Patents by Inventor Philip Arthur Hipskind

Philip Arthur Hipskind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists
    Publication number: 20080207732
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: March 13, 2006
    Publication date: August 28, 2008
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Takako Takakuwa
  • Imidazopyridazine Compounds
    Publication number: 20080153828
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Application
    Filed: April 3, 2006
    Publication date: June 26, 2008
    Inventors: Elizabeth Aaron Collins, Pablo Garcia-Losada, Chafiq Hamdouchi, Philip Arthur Hipskind, Jianliang Lu, Takako Takakuwa
  • Imidazopyridazine Compounds
    Publication number: 20080113978
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Application
    Filed: March 20, 2006
    Publication date: May 15, 2008
    Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafip Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
  • Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
    Patent number: 7314937
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: January 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson
  • Thiophene-and thiazolesulfonamides as antineoplastic agents
    Patent number: 7250430
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: July 31, 2007
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
    Patent number: 7229987
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson
  • Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
    Patent number: 7183320
    Abstract: The present invention provides antitumor compounds of the formula (I), and antitumor methods
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: February 27, 2007
    Assignee: Eli Lilly and Company
    Inventors: Chuan Shih, Cora Sue Grossman, Karen Lynn Lobb, Thomas Hughes Corbett, Ho-Shen Lin, Philip Arthur Hipskind
  • Thiophene-amd thiazolesulfonamides as antineoplastic agents
    Patent number: 7084170
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: August 1, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Thiophene-amd thiazolesulfonamides as antineoplastic agents
    Publication number: 20040198784
    Abstract: The present invention provides antineoplastic compounds of the formula (D).
    Type: Application
    Filed: March 26, 2004
    Publication date: October 7, 2004
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso de Dios
  • Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
    Publication number: 20040110748
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 10, 2004
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson
  • Benzimidzolyl neuropeptide Y receptor antagonists
    Publication number: 20020007071
    Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.
    Type: Application
    Filed: November 30, 2000
    Publication date: January 17, 2002
    Inventors: Thomas Charles Britton, Robert Frederick Bruns, Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
  • Benzimidzolyl neuropeptide Y receptor antagonists
    Patent number: 6255494
    Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: July 3, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Robert Frederick Bruns, Jr., Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
  • 2-acylaminopropanamides as growth hormone secretagogues
    Patent number: 5773441
    Abstract: This invention provides a series of novel substituted propanamides which are useful in the a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiological conditions which comprise administering a growth hormone secretagogue as described in the present invention in combination with growth hormone releasing hormone.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: June 30, 1998
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Jeffrey Alan Dodge